Search
  • Search

    Market Consultation, Large Cancer Panel Test HUS 324-2025

    HUS-yhtymä

    Market Consultation, Large Cancer Panel Test HUS 324-2025

    1. Planning notice published

      May 7, 12:09 PMMay 7, 2026 12:09 PM

    2. Change in planning

      May 13, 5:25 AMMay 13, 2026 5:25 AM

    3. Questions deadline

      May 14, 9:00 AMMay 14, 2026 9:00 AM

    Brief

    Finland: Tenders/HUS-yhtymä/Market Consultation, Large Cancer Panel Test HUS 324-2025

    Published deadline passed

    The published deadline has passed. For multi-stage competitions a later tender deadline may still apply — check the notice or portal for the current phase.

    Brief

    Medisinsk og laboratorieutstyr

    HUS-yhtymä is planning the procurement of large cancer panel tests, divided into Lot A for solid tumors and hematological malignancies, and Lot B for cell-free DNA, including analysis software for both. The purpose of this market consultation is to gather comprehensive information to support the preparation of the procurement.

    About the bid

      This document is not a contract notice or a call for tenders, but a market consultation in accordance with Section 65 of the Finnish Procurement Act, carried out by the contracting authority (also "HUS Group" and "Client") as described in this request for information. The purpose of this request for information is to clarify issues related to the procurement referred to in the title. The objective of the request is to obtain comprehensive information on the subject matter of the procurement in order to support the preparation of the procurement, so that any potential competitive tendering procedure can be conducted in the most appropriate manner possible. The contracting authority does not commit to carrying out the procurement. Decisions on whether to initiate a possible procurement process will be made after the market consultation. Summary of the description of the procurement: The HUS Group requests tenders for a large cancer panel test (also "product") for HUS Diagnostic Center. Laboratory of Genetics at HUS (Helsinki University Hospital) Diagnostic Center is an SFS-EN ISO 15189:2022 accredited laboratory providing diagnostic genetic testing services to all patients at Helsinki and Uusimaa Hospital District. The services include analysis of both constitutional samples and malignancies. The laboratory provides sequencing services mainly using local sequencing capacity (Illumina NovaSeq 6000, NovaSeq X Plus, Ion GeneStudio S5 Prime equipment). The large cancer panel test is intended for detection of small nucleotide variants (SNVs), indels, gene fusions, copy number variations (CNVs), microsatellite instability (MSI), homologous recombination deficiency (HRD), and tumor mutation burden (TMB) relevant for the genetic profiling of solid tumor samples and/or hematological malignancies as well as plasma samples for cfDNA analysis. The procurement is divided into LOT A and LOT B: LOT A - This lot contains panels for solid tumors and hematological malignancies and analysis software. - This test is based on analysis of total nucleic acids (RNA and/or DNA) extracted from paraffin embedded specimens and/or fresh-frozen specimens - This lot includes an option for special panel for salivary gland tumors and an option custom panel. - The HUS Group will decide separately on the use of the option. LOT B - This lot contains panel for cell-free DNA and analysis software. - This test is based on analysis of cell-free DNA from plasma samples For more information please read the Appendixes.

      Contact name
      HUS Group
      Contact phone
      +358 94711
      Contact email
      kilpailutus.diagnostiikka@hus.fi
      Address
      Uutistie 5, 01770 Vantaa

    Custom Assessment Criteria

    Start a free trial to ask your own questions about the tender and get AI-generated answers.

    Award Criteria

      Found no award criteria in the contract notice.

    Qualification requirements

      Found no qualification requirements in the contract notice.

    Previous Contract Winners

    Start a free trial to see who has won similar tenders for this buyer.

    See the full notice

    Contracting authority
    HUS-yhtymä
    Title
    Market Consultation, Large Cancer Panel Test HUS 324-2025
    Type
    Planning
    Main code
    33000000Medical equipments, pharmaceuticals and personal care products
    Supplemental codes
    72000000IT services: consulting, software development, Internet and support

    Supplemental codes added by Cobrief

    33124130Diagnostic supplies
    33696500Laboratory reagents
    85148000Medical analysis services
    Location
    Helsinki-Uusimaa

    Active similar competitions

    • HUS-yhtymä

      Laboratorie- og analyseutstyr

      MLPA-Based CNV Testing for BRCA1/BRCA2

      HUS Group, the joint authority for Helsinki and Uusimaa, needs an MLPA (Multiplex Ligation-dependent Probe Amplification) assay for the detection of copy number variations (CNVs) in BRCA1 and BRCA2 genes, including all reagents, controls, consumables, software, licenses, and other components required for routine use and generation of reportable patient results. The contract period is 2 years, after which it continues indefinitely until terminated. The estimated annual consumption is approximately 1600 reportable patient samples, to be delivered to the HUSLAB Laboratory of Genetics in Helsinki-Uusimaa, Finland. The award criterion is the lowest total comparison price.

      CompetitionOct 7, 2026
      Nov 9, 2026(11 days)

    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      REQUEST FOR INFORMATION: SPRI Beads

      HUS-yhtymä is planning the procurement of DNA size selection reagents based on paramagnetic beads, utilizing SPRI technology for selective binding and purification of DNA fragments, to be used in next-generation sequencing (NGS) library preparation. Suppliers can provide feedback and input by submitting a response via email to kilpailutus.diagnostiikka@hus.fi, addressing all requirements, providing requested information and documentation, and identifying any concerns or proposed amendments to the draft agreement.

      PlanningAug 18, 2026
      Nov 1, 2026(3 days)

    • Satakunnan hyvinvointialue

      Laboratorie- og analyseutstyr

      Markkinavuoropuhelukutsu - syndromiset molekyylipaneelit

      Satakunnan hyvinvointialue suunnittelee syndromisten molekyylipaneelien hankintaa, mukaan lukien positiivisten veriviljelyjen BCID-paneeli, meningiitti/enkefaliittipaneeli (ME) ja laaja respiratorinen paneeli, sekä mahdollisesti trooppisten kuumetautien diagnostiikkaan soveltuva syndrominen molekyylipaneeli. Hankinnan tavoitteena on selvittää markkinoilla olevat ratkaisut ja niiden soveltuvuus laboratorion toiminnallisiin tarpeisiin, ja nykyinen käyttö perustuu BIOFIRE FILMARRAY TORCH -järjestelmään. Toimittajat voivat antaa palautetta ja panoksia osallistumalla kahdenkeskisiin Teams-kokouksiin, joihin tulee ilmoittautua etukäteen.

      PlanningOct 9, 2026

    • HUS-yhtymä

      Laboratorie-kits og reagenser

      Automaattinen nukleiinihappojen eristyslaite

      HUS-yhtymä suunnittelee automaattisen nukleiinihappojen eristyslaitteen hankintaa HUS Diagnostiikkakeskuksen Kliinisen mikrobiologian nukleiinihappoanalytiikkaan, sisältäen laitteen, varalaitteen tai kaksi erillistä eristysmoduulia sekä tarvittavat reagenssit ja tarvikkeet. Hankittavalla laitteella on tarkoitus eristää bakteeri-DNA:ta useista eri näytemateriaaleista, ja eristetyn tuotteen tulee olla validoitu bakteerien 16S-geenin PCR-monistamiseen Sanger-sekvensoinnilla. Toimittajia pyydetään tutustumaan liitteenä oleviin kysymyksiin ja toimittamaan vastaukset sähköpostitse osoitteeseen kilpailutus.diagnostiikka@hus.fi. bioMérieux Suomi OY:llä on todennäköisesti sopimus tällä hetkellä.

      PlanningSep 16, 2026
      Jan 16, 2027(79 days)

    • HUS-yhtymä

      Medisinsk og laboratorieutstyr

      Request for information: Radioactive seeds (I-125) and plaques (Ru-106) used in eye brachytherapy

      HUS Group is planning the procurement of radioactive products, specifically Iodine-125 (I-125) brachytherapy seeds and Ruthenium-106 (Ru-106) eye plaques/applicators, along with related accessories for the treatment of epibulbar and intraocular tumors. Suppliers are asked to provide information on their product portfolios, typical delivery times, and available options for accessories, quality assurance, and treatment planning systems by submitting their responses via email to kilpailutus.tiimi@hus.fi. Eckert & Ziegler BEBIG GmbH likely has the contract today.

      PlanningOct 5, 2026
      Jan 25, 2027(88 days)